Related Experiment Videos
New endocrine approaches in the treatment of breast cancer
1Dept of Obstetrics and Gynecology, University of Frankfurt, Germany.
Abstract:
As a result of tamoxifen becoming the first endocrine compound with proven activity in breast cancer, a. broad spectrum of new substances have been tested and several are now available for clinical use. New pure antiestrogens show no estrogenic activity as a result of different receptor binding, and some other derivatives of tamoxifen demonstrate varied toxicity profiles. The second and third generation of aromatase inhibitors can selectively inhibit the aromatase enzyme in the peripheral tissue and perhaps even in tumor cells. Gonadotrophin-releasing hormone (GnRH)-analogues can suppress ovarian function in premenopausal patients and thus prevent surgical ovarectomy. The value of a new group of anti-progestional substances has not yet been clarified. In this overview the most important compounds are reviewed for efficacy and toxicity in breast cancer patients.
Insights
Tamoxifen revolutionized breast cancer treatment, leading to new endocrine therapies. This review covers newer antiestrogens, aromatase inhibitors, and GnRH-analogues, evaluating their efficacy and toxicity in patients.
Area of Science:
- Endocrinology
- Oncology
- Pharmacology
Background:
- Tamoxifen was the first endocrine therapy for breast cancer.
- Numerous new endocrine agents have since been developed and approved for clinical use.
Purpose of the Study:
- To review the efficacy and toxicity of key endocrine compounds used in breast cancer treatment.
- To provide an overview of novel antiestrogens, aromatase inhibitors, and GnRH-analogues.
Main Methods:
- Literature review of endocrine therapies for breast cancer.
- Analysis of efficacy and toxicity data for selected compounds.
Main Results:
- New pure antiestrogens lack estrogenic activity.
- Tamoxifen derivatives exhibit varying toxicity profiles.
- Aromatase inhibitors (2nd and 3rd generation) selectively inhibit aromatase.
- GnRH-analogues suppress ovarian function in premenopausal women.
- The role of anti-progestional substances is still under investigation.
Conclusions:
- A range of endocrine therapies are available for breast cancer.
- These agents offer improved selectivity and different toxicity profiles compared to earlier treatments.
- Further research is needed to clarify the role of certain agents, such as anti-progestins.